Q-omics provides the consensus-scored H4C11 profile across patient tissues and cancer cell-line models. H4C11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H4C11 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, H4C11 RNA expression shows 18,049 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where H4C11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H4C11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H4C11 survival associations across molecular data types. H4C11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H4C11 RNA expression–survival associations across cancer types. High H4C11 expression shows unfavorable associations in KIRC, SKCM, LGG and KICH, but favorable associations in ACC and OV. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H4C11 RNA expression.
This table summarizes H4C11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for H4C11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H4C11 shows higher tumor expression in KIRC, HNSC, LIHC, BRCA, KIRP and LUSC. The KIRC box plot shows higher H4C11 RNA expression in tumor versus normal tissue (log2 FC = +0.299, t-test p < 0.001).
This table shows molecular features associated with H4C11 in patient tissues and cancer cell lines. In patient samples, H4C11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H4C11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
